Beta cell death may occur both after islet isolation and during infusion back into recipients undergoing total pancreatectomy with islet autotransplantation (TPIAT) for chronic pancreatitis. We measured the novel beta cell death marker unmethylated insulin (INS) DNA in TPIAT recipients before and immediately after islet infusion (n = 21) and again 90 days after TPIAT, concurrent with metabolic functional assessments (n = 25). As expected, INS DNA decreased after pancreatectomy (p = 0.0002). All TPIAT recipients had an elevated unmethylated INS DNA ratio in the first hours following islet infusion. In four samples (three patients), INS DNA was also assessed immediately after islet isolation and again before islet infusion to assess the impact of the isolation process: Unmethylated and methylated INS DNA fractions both increased over this interval, suggesting death of beta cells and exocrine tissue before islet infusion. Higher glucose excursion with mixed-meal tolerance testing was associated with persistently elevated INS DNA at day 90. In conclusion, we observed universal early elevations in the beta cell death marker INS DNA after TPIAT, with pronounced elevations in the islet supernatant before infusion, likely reflecting beta cell death induced by islet isolation. Persistent posttransplant elevation of INS DNA predicted greater hyperglycemia at 90 days.
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Introduction
Total pancreatectomy with islet autotransplantation (TPIAT) is performed to relieve pain in patients with severe chronic pancreatitis (1) . The islet autotransplantation component is intended to minimize postoperative diabetes by preserving endogenous beta cell mass, but success is complicated by postisolation and postinfusion loss of beta cells. The islet isolation procedure itself induces high rates of beta cell apoptosis (2, 3) . Subsequently, infusion of islets directly into the portal vasculature stimulates an instant blood-mediated inflammatory reaction (IBMIR) (4) that, along with hypoxia and hyperglycemia (5-9), may further contribute to beta cell loss. These same limitations apply to allogenic islet transplantation for type 1 diabetes (T1D).
Islet mass is measured in the islet isolation laboratory before intraportal islet infusion (1) . Until recently, however, the islet transplant field has lacked biomarkers to detect beta cell loss (10, 11) . Such markers may be critically important for addressing barriers to success in islet transplantation. Recently, our group developed a method to measure DNA of beta cell-derived unmethylated insulin (INS) in serum and used it to identify beta cell loss in patients with T1D (12, 13) . This assay differentiates unmethylated and methylated CpG sites within an exon in the INS gene found in bisulfite-treated circulating DNA. Unmethylated CpG sites are characteristic of actively transcribed genes. Because cellular DNA is released into the serum with cell death, the relative level of INS DNA with unmethylated versus methylated CpG sites reflects beta cell loss because only within the beta cell is INS unmethylated for transcription (14) (15) (16) (17) . We reported previously that the ratio of unmethylated:methylated INS DNA is elevated in early onset T1D, when beta cell destruction is occurring; is low in late-stage T1D, when few beta cells remain; and decreases following successful treatment of patients with new-onset T1D with anti-CD3 mAb (14) . We also found previously that the relative level of unmethylated INS DNA increased following TPIAT (12) , but the basis for the increase and the levels of beta cell death in the days following transplantation were not addressed. This prospective study assessed the utility of unmethylated INS DNA as a beta cell biomarker in TPIAT recipients.
Methods

Participants and study protocol
Patients aged ≥11 years undergoing TPIAT at the University of Minnesota for intractable chronic or recurrent acute pancreatitis were enrolled prospectively. Repeated serum samples were drawn from 21 TPIAT recipients before surgery (day À2) and after pancreatectomy but before islet infusion, and then at 15, 30, and 60 min; 3, 6, 12, and 24 h; and 3, 5, 7, 14, 21, 30, and 90 days after end of islet infusion to measure unmethylated INS DNA levels. Based on observations in the first four participants, the samples collected after pancreatectomy and 15 and 30 min after the end of islet infusion were added and collected for only the last 17 participants. The same 21 participants and an additional four TPIAT recipients returned at 90 days after TPIAT for unmethylated INS DNA sampling and tests of islet function and glycemic control.
To investigate whether beta cell loss resulted from islet isolation versus islet infusion, we collected supernatant from the islet grafts of three other TPIAT recipients immediately after islet isolation in the islet laboratory and then again immediately before islet infusion.
The study was approved by the University of Minnesota and Yale University institutional review boards. Informed consent or parental informed consent with patient assent was obtained.
Surgical procedure and islet isolation techniques
Total or completion pancreatectomy was performed, with partial duodenectomy, Roux-en-Y duodenojejunostomy, splenectomy and cholecystectomy, as described previously (1, 18) . Islet isolation was performed with collagenase distention followed by mechanical digestion using the semiautomated method of Ricordi et al (19, 20) . COBE purification (COBE 2991 cell processsor; Terumo BCT, Lakewood, Colorado) was performed only when tissue volume exceeded 0.25 mL/kg of body weight (21) . Islet counts, expressed as total islet equivalents (IEQs), were obtained by manual count with dithizone staining. Following islet isolation and islet counting, the final islet product was washed twice with fresh transplant media and then placed in a single bag or divided between two bags, depending on tissue volume.
For the three patients from whom samples from the islet product were obtained, supernatant samples were collected twice: first from the islet product suspended in 100 mL of CMRL medium immediately after islet washing and second from the final islet product, suspended in 200 mL of CMRL medium, collected in the operating room (OR) during infusion. Paired samples were obtained from four bags of islet product from three TPIAT recipients in the laboratory and OR supernatant for analysis.
Islets were infused primarily into the portal vein with monitoring of portal pressures and/or flow. If portal hypertension prohibited infusion of all islets intraportally (n = 8 cases), then a portion of the islets were placed in the peritoneal cavity or a similar site. The end time of the portal infusion was designated as time 0 for lab draws.
Assays for unmethylated INS DNA
The unmethylated INS DNA assay used droplet digital polymerase chain reaction (PCR), as described previously (12) . DNA was purified from 200 lL of serum using QIAamp DNA blood kits, as suggested by the manufacturer (Qiagen, Valencia, CA), with a modified incubation period of 20 min at 45°C in the final step. DNA was bisulfite treated using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA). We measured the levels of unmethylated INS DNA by droplet digital PCR targeting two methylation-sensitive sites of the human INS gene in positions +396 and +399 from the transcription start site (hg19_knownGene_uc021qcd.1 range=chr11:2181009-2182439) (12, 13) . Each 25-ll volume consisted of Droplet Digital PCR supermix (Bio-Rad Laboratories, Hercules, CA), 900 nM of primer, 250 nM of probe and 5 lL of sample. The mixture and droplet generation oil were loaded onto a droplet generator (Bio-Rad Laboratories), and the generated droplets were transferred to a 96-well PCR plate. The PCR reaction was run on a thermal cycler with 10-min activation at 95°C, 409 a two-step amplification protocol (30 s at 94°C denaturation and 60 s at 58°C), and a 10-min inactivation step at 98°C. The DNA content of the droplets was analyzed with a QX100 droplet reader (Bio-Rad Laboratories) and QuantaSoft analysis software (Bio-Rad Laboratories). Discrimination between droplets that did and did not contain the target (positive and negative, respectively) was achieved by applying a fluorescence amplitude threshold based on the amplitude read from the negative template control. For each sample, the "ratio" of unmethylated INS DNA was calculated as the unmethylated counts divided by the sum of the unmethylated and methylated counts (U/[M+U]). The normal ratio was defined from healthy nondiabetic control participants (n = 49, mean plus or minus standard deviation [SD] of 0.129 AE 0.045) as ≤0.219 (i.e. mean + 2 SD). Higher values were considered elevated.
Assays for islet engraftment and beta cell function at day 90 after transplant
Patients returned at day 90 AE 21 days after TPIAT for metabolic assessments. Day 90 was selected because islet revascularization was complete (9). On two separate mornings following an overnight fast, patients underwent three tests: On the first morning, patients underwent a mixed-meal tolerance test (MMTT), and on the second morning, patients underwent an intravenous glucose tolerance test (IVGTT) followed immediately by a glucose-potentiated arginine-induced insulin secretion (GPAIS) study.
MMTT was performed by measuring glucose and C-peptide before and at 30-min intervals for 2 h after drinking Boost HP (6 mL/kg, maximum 360 mL; Nestl e HealthCare Nutrition, Fremont, MI) (22) . The areas under the curve (AUCs) for glucose and C-peptide were calculated by the trapezoidal rule. IVGTT and GPAIS protocols were described previously in islet transplant recipients (22, 23) . IVGTT was performed by administering 0.3 gm/kg dextrose. Samples were collected before and 2, 3, 4, 5, 7, and 10 min after administering dextrose. Acute insulin response to glucose (AIRg) and acute C-peptide response to glucose (ACRg) were calculated from the AUC for the 10-min interval subtracting out the baseline. At 10 min after dextrose administration, a variable rate infusion of 20% dextrose was started and continued for 45 min and adjusted to maintain target blood glucose of 230 mg/dL. At the end of the 45-min clamp period, two baseline serum samples were obtained; 5 gm arginine was administered over 30 s; and insulin and C-peptide were obtained at 2, 3, 4, and 5 min. Glucose-potentiated acute insulin response to arginine (AIRpot) and glucose-potentiated acute C-peptide response to arginine (ACRpot) were calculated as the mean of the 2-to 5-min values minus the prearginine baseline value (24) .
Statistics
Summary data are reported as median (interquartile range [IQR] ). Changes in the ratio of unmethylated INS DNA after baseline were tested using a mixed linear model (which generalizes a repeated-measures analysis using person and time after baseline as the fixed and random effects, respectively). Levels of unmethylated and methylated INS DNA and the ratio were compared immediately after isolation versus the time of infusion using paired t-tests. Finally, the association of functional measures with an elevated ratio at follow-up was tested by multiple linear regression with a primary predictor of elevated INS DNA ratio (yes vs. no) and an adjuster of IEQs per kilogram of body weight. Separate analyses were done for elevated ratios during the period of 3 to 30 days after TPIAT and at 90 days after TPIAT.
The half-life of unmethylated INS DNA was calculated by fitting an exponential function to the repeated measures of unmethylated INS DNA levels after islet infusion, in which each patient had his or her own baseline values. The parameter k characterizing the exponential decay was obtained by maximum likelihood estimation. The half-life was then calculated as t 0.5 = log(0.5)/log(k).
Results
Participant characteristics
TPIAT recipients had a median age of 28.3 years (IQR 18.0-42.1 years) and 314 600 IEQs (IQR 169 649-425 500 IEQs) transplanted (Table 1) .
Unmethylated INS DNA before and after islet infusion Serum samples were obtained before and after complete pancreatectomy. As expected, the ratio of INS DNA was significantly lower after the procedure (p = 0.0002) (Figure 1) . Before pancreatectomy, samples from 7 of 21 participants were above the normal-range ratio for unmethylated:total INS DNA (>0.219), suggesting increased beta cell death related to chronic pancreatitis. After pancreatectomy and before islet infusion, 2 of 18 levels were above the normal range, and the median ratio was 0.152 (IQR 0.121-0.179), indicating that the targeted exon is unmethylated in a small but detectable proportion of DNA molecules from nonpancreatic tissue.
The ratio was elevated immediately after islet infusion in all recipients in the first 3 h, with variable later peaks over the 30-day sampling period (Figure 2 ). Ratios of unmethylated:total INS DNA peaked within the first several hours after TPIAT at a median of 2.5-fold (IQR 2.0-to 3.3-fold) above pre-TPIAT baseline (p < 0.001). The ratios did not differ in those with intraportal versus intraportal plus peritoneal islet grafts; adolescents had lower elevations in the ratio than adults in the 15-min to 1-h postinfusion samples only (p = 0.005) but similar levels beyond 1 h. The half-life of unmethylated INS DNA in serum was 2.2 h (95% confidence interval 1.7-2.9 h).
Source of unmethylated INS DNA
To investigate whether these early ratio elevations were caused by beta cell death that occurred before infusion, from the trauma of islet isolation, we measured the levels of INS DNA in four preparations of islet product in the laboratory immediately after isolation and in the OR at infusion. Between the end of isolation and subsequent infusion (40-75 min), there was a significant increase in the total counts of unmethylated INS DNA (p = 0.02) and methylated INS DNA (p = 0.04) and, to a lesser extent, the ratio of unmethylated:total INS DNA in the cell-free supernatant of the islet product (p = 0.07) (Figure 3 ). The islet products had low purity, %10-25%, so elevation in unmethylated INS DNA reflects death of the beta cell component, whereas elevation in methylated INS DNA in the Patients are maintained on insulin per protocol through day 90 to maintain euglycemia. ACRg, acute C-peptide response to glucose; ACRpot, glucose potentiated acute C-peptide response to arginine; AIRg, acute insulin response to glucose; AIRpot, glucose potentiated acute insulin response to arginine; AUC, area under the curve; HbA1c, hemoglobin A1c; IEQ, islet equivalent; IQR, interquartile range.
supernatant reflects death of non-beta islet cell components and exocrine tissue composing the transplant graft.
Unmethylated INS DNA and functional beta cell testing after TPIAT Because all patients had elevated unmethylated INS DNA ratios immediately after islet infusion, we considered whether elevation of this ratio late after TPIAT was a predictor of 90-day outcomes. In the measures between days 3 and 30, 23 of 119 ratios in 11 of 21 patients (52%) were elevated (i.e. >0.219), which we termed "late elevations." We considered day 90 separately (after islet engraftment), and elevated ratios were still present in 7 of 24 patients (29%), termed "day 90 elevations."
After adjusting for IEQs per kilogram of body weight transplanted, patients with late or day 90 elevations did not differ significantly from those without elevations in insulin or C-peptide secretory measures including AUC for C-peptide, AIRg, ACRg, AIRpot or ACRpot. High MMTT AUC for glucose, however, was significantly associated with an elevated unmethylated INS DNA ratio at day 90 after adjusting for IEQs per kilogram of body weight transplanted (p = 0.0009) (Figure 4) , suggesting that ongoing beta cell loss at day 90 was associated with meal-induced hyperglycemia.
Measures of islet function at day 90 did not differ between those with intraportal-only and intraportal plus peritoneal grafts or in adults versus adolescents (p > 0.15 for all).
Discussion
Diabetes outcomes after TPIAT vary for any transplanted islet mass, likely because of differences in beta cell survival following both isolation and transplantation (1) . Beta cell apoptosis can be induced by islet isolation itself (2, 25, 26) and by the innate inflammatory responses that follow intraportal islet infusion (4,10,27); until recently, however, beta cell biomarkers to assess posttransplant beta cell death have been largely lacking. We observed that the ratio of unmethylated INS DNA declines after removal of the pancreas. It then is elevated several-fold over prepancreatectomy baseline in all recipients immediately after isolation and infusion of the islet product, confirming our group's previous observations that this is a marker of beta cell death. A dramatic rise in unmethylated and methylated INS DNA within the islet supernatant in the short (%1 h) period before islet infusion suggests that much of the immediate post-islet infusion peak results from islet isolation itself. Late elevations beyond the first postoperative day varied among recipients, suggesting inconsistent later beta cell loss. These results highlight an opportunity to better protect beta cells during islet isolation and the first several months after islet transplant to optimize diabetes results after TPIAT.
A striking rise in INS DNA was observed in the islet product supernatant before infusion. This suggests a significant die-off of beta cells, other islet cell components and exocrine tissue induced by the isolation procedure; we hypothesize that this accounts for a substantial proportion of the peak in the unmethylated INS DNA ratio in the first hour after islet infusion. In contrast, later elevations may be better explained by detrimental postinfusion events including IBMIR and beta cell hypoxia (9, 27) .
Elevations in the unmethylated INS DNA ratio did not predict insulin secretory measures at 3 mo, the period after which islet revascularization is largely complete and beta cell functionality restored (8, 9) . Because the half-life of the unmethylated INS DNA is short, much more frequent monitoring may be needed to accurately account for all beta cell death occurring during islet engraftment. Nevertheless, compared with a previously established normal healthy control cohort, more than half of our TPIAT recipients clearly had periods of beta cell loss even beyond the first 24 h after transplant. The nearly 30% of patients with persistent elevated ratios of unmethylated INS DNA at day 90 exhibited greater glycemic excursion to an MMTT, adjusting for IEQs per kilogram of body weight transplanted. This suggests that either these recipients' islet grafts have poorer viability, resulting in hyperglycemia, or that recurrent hyperglycemia itself triggers ongoing loss of beta cells (6, 28) .
Further study is warranted to determine the clinical utility of the unmethylated INS DNA marker. This measure may be useful for studying strategies to improve early beta cell survival, including refinements in isolation, and antiinflammatory strategies that have been proposed but remain untested in randomized trials. Although we hypothesize that much of the early elevation in unmethylated INS DNA is attributable to beta cell loss induced by isolation, the relative impact of isolation, IBMIR and cotransplanted acinar tissue on beta cell death merits further mechanistic study. Post hoc analyses suggest lesser elevations in the INS DNA ratio in adolescents versus adults, although functional outcomes were no different between these groups. This raises speculation about better resilience of "young" beta cells to isolation and transplant injury. Very young children, previously shown in our population to have better diabetes outcomes than adolescents and adults, were excluded (18).
Our data and previous studies support the specificity of unmethylated INS DNA for beta cell loss; CpG sites within the INS gene of beta cells are unmethylated to transcribe insulin (12) (13) (14) (15) (16) . It is possible, however, that these same sites may be unmethylated rarely in nonbeta cells, leading to a nonspecific background "signal" being present even after pancreatectomy. Our studies from high-throughput sequencing suggest this occurs in %5% of reads (data not shown). Furthermore, we cannot exclude that surgical pancreas manipulation might affect INS DNA during and immediately after surgery, but the reduction in INS DNA ratios after pancreatectomy suggests this is not a significant confounder.
We conclude that beta cell death induced by islet isolation is nearly universal in TPIAT recipients. Beta cell death may persist through islet engraftment, even up to 3 mo after TPIAT. Unmethylated INS DNA may represent a useful beta cell biomarker for monitoring beta cell death in the islet product before transplant and as islet isolation strategies evolve and as a marker for ongoing post-islet infusion loss in TPIAT recipients.
